No Data
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.
HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $30
HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target from $33 to $30.
EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges